Under construction – not a live service
Sign in
Taking people in JapanNo phase

Observing Brentuximab Vedotin Use in Children and Teens With Hodgkin Lymphoma

Watches children and teens with Hodgkin lymphoma treated with brentuximab vedotin for side effects.

Plain-language title generated from the registry record
Registry title: A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Key facts

Where
Tokyo, JapanSee the site

Where in Japan

  • TokyoTokyo, JapanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Takeda
Trial code
NCT05481437
Record updated
13 April 2026
Original description
This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.Read full original descriptionShow less

Specified Drug Use Surveillance for ADCETRIS Intravenous Infusion 50 mg -Untreated CD30 Positive Hodgkin Lymphoma (Pediatric)

This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Brentuximab Vedotin especially myelosupression, peripheral neuropathy, and lung disorder.

During the study, pediatric participants with HL will take Brentuximab Vedotin injection and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine) according to their clinic's standard practice. The study doctors will check for side effects from Brentuximab Vedotin for 26 weeks.

Inclusion: Treatment-naive participants; CD30 positive participants; Participants treated with the study drug in combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD); Participants aged < 18 years at the start of this drug.

Exclusion: Participants with contraindications to the study drug.

ClinicalTrials.gov NCT05481437